Assembly Bio Spikes After Early-stage Data for Gilead-partnered Hep B Therapy
Mizuho CEO Sees Global Boom in M&A After Trump Takes Office
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
Needham Reiterates Hold on Neurocrine Biosciencesto Hold
Neurocrine Biosciences Analyst Ratings
Gilead Sciences Acquires 7.85M Xilio Therapeutics Shares At $1.04 Each, Raising Ownership To Over 10%, Along With 6.1M Pre-Funded Warrants Capped At 19.99% Ownership
(GILD) - Analyzing Gilead Sciences's Short Interest
Gilead Raises Assembly Bio Stake to ~30%
Wells Fargo Maintains Overweight on Argenx, Raises Price Target to $723
Argenx Analyst Ratings
Peering Into Exelixis's Recent Short Interest
$1000 Invested In Argenx 5 Years Ago Would Be Worth This Much Today
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved With BHV-1300, Gains Analyst Approval
Gilead Gets FDA Breakthrough Therapy Status for Trodelvy
Repligen Analyst Ratings
Expert Outlook: Exelixis Through The Eyes Of 19 Analysts
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Exelixis Analyst Ratings